Neovii to Develop a COVID-19 Vaccine with Tel Aviv University

Neovii has signed a research and licensing agreement with Tel Aviv University to develop a COVID-19 vaccine.

The candidate vaccine will target the "spike" protein that the virus uses to bind to cell receptors in the human body.

Neovii will retain exclusive rights to its patented platform for the rapid development of new vaccines.